Cesar Gentille, MD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: COM - Internal Medicine

Cancer Research Interest

• Disease Site Focus: Leukemia/ Lymphoma, Hematologic Malignancies
• Research Focus Area: Treatment, Health Disparities, Diagnosis/ Prognosis
• Type of Research: Clinical, Population Sciences
• Research Keywords: Lymphoma, stem cell transplant/cellular therapy, cutaneous lymphoma
• Research Interest Statement: My clinical focus is on malignant hematology, hematopoietic cell transplant and cellular therapy. My field of interest is lymphoproliferative disorders particularly rare diseases such as T-cell cutaneous lymphomas as well as cellular therapy. My previous research experience includes retrospective data analysis of outcomes of patients with diverse hematological malignancies including acute myeloid leukemia, primary and secondary central nervous system lymphoma (CNS) and T-cell lymphoma as well as epidemiological dataset analysis of rare disease using the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR). During this time, I acquired the knowledge necessary to formulate and conduct clinical research, learned about the resources, the timeline construction and the organization needed to implement these skills and publish our results. This is supported by the record of successful and productive research accomplished including a study describing the incidence and resistance spectrum of multi-drug resistant bacterial infections in patients with various malignancies such as acute and chronic leukemia (myeloid and lymphocytic), myelodysplastic syndrome and amyloidosis. This project was one of the winners of the 2017 American Society of Hematology (ASH) HONORS award which provided funding for the study. Currently, I am a PI/co-investigator in a SWOG cooperative group trial as well as other studies in lymphomas including phase I and phase II CAR-T trials.

Contact Information

• Email Address: CGentille@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)” (NCT05409066)
• “A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)” (NCT04637763)
• “A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)” (NCT05578976)
• “An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy” (NCT05972720)
• “S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma” (NCT05633615)

Recent Publications

• Hamilton MP, Craig E, Gentille Sanchez C, [et al.]. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood advances. 2024 8(12):3314-3326. PMID: 38498731. PMCID: PMC11258628.
• Fugere T, Baltz A, Mukherjee A, [et al., including Gentille Sanchez CG]. Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity. Cancers. 2023 15(21). PMID: 37958323. PMCID: PMC10647774.
• Burns EA, Sanchez CG, Mathur S, [et al.]. Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry. Annals of hematology. 2023 102(5):1111-1120. PMID: 36922432.
• Ensor AM, Sanchez CG, Ensor JE, Anand K. Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis. Medicine. 2021 100(40):e27359. PMID: 34622835. PMCID: PMC8500583.